Free tool
Rare disease stocks
We cover 42 companies grouped under the Rare disease theme. The median market value in the group is $264.31M. Across the group, the median move over the past trading day is +0.43%. 49% of the 39 with a 200-day average trade above it. Price change over the past year runs from −46.6% to +166.8% across the middle 80 percent of the group, with a median of −8.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
42 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VX1.DE | Vertex Pharmaceuticals Incorporated | 475.00 EUR | +10.21% | +23.55% | +41.64% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $549.02 | +0.13% | +22.11% | +40.77% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $241.82 | +0.67% | −39.23% | −46.60% |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | 204.00 EUR | −19.59% | −40.19% | −10.21% |
| 0JAV.L | Insmed Incorporated | $125.00 | +0.43% | −28.28% | −7.52% |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A. | 52.70 EUR | +2.53% | +10.68% | +1.80% |
| 0JDI.L | Ionis Pharmaceuticals, Inc. | $63.37 | +3.44% | −19.72% | +47.26% |
| ABVX.PA | ABIVAX Société Anonyme | 102.30 EUR | −5.63% | −11.04% | +48.91% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% |
| 0HI3.L | Arrowhead Pharmaceuticals, Inc. | $89.35 | +3.26% | +32.80% | +294.59% |
| CAMX.ST | Camurus AB (publ) | 615.00 SEK | −1.68% | +0.49% | −15.35% |
| 0RD1.L | Camurus AB (publ) | 609.98 SEK | −0.21% | −0.53% | −15.10% |
| 0L35.L | Sarepta Therapeutics, Inc. | $18.51 | +1.60% | −13.25% | −0.06% |
| 0LIF.L | Ultragenyx Pharmaceutical Inc. | $26.19 | +1.39% | +12.52% | −13.39% |
| 0HB0.L | Agios Pharmaceuticals, Inc. | $34.05 | +0.18% | +26.06% | −13.00% |
| DBV.PA | DBV Technologies S.A. | 2.53 EUR | +5.42% | −22.51% | +60.13% |
| GNFT.PA | Genfit S.A. | 14.30 EUR | +5.30% | +172.38% | +310.45% |
| 0QNA.L | Basilea Pharmaceutica AG | 65.80 CHF | +2.73% | +20.16% | +41.96% |
| AYJ.DE | Valneva SE | 2.98 EUR | +35.29% | −23.93% | −21.89% |
| 0KBU.L | Omeros Corporation | $18.44 | −4.75% | +11.14% | +332.86% |
| 0OB3.L | Valneva SE | 2.87 EUR | +0.75% | −23.95% | −25.05% |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% |
| 0QN1.L | Santhera Pharmaceuticals Holding AG | 15.66 CHF | −1.88% | +29.00% | +11.86% |
| 0T6G.L | Q32 Bio Inc. | $16.34 | +7.94% | — | — |
| 0AB6.L | Hyloris Pharmaceuticals SA | 4.38 EUR | −1.79% | −38.83% | −33.23% |
| CRNO-B.ST | Cereno Scientific AB (publ) | 4.71 SEK | +0.13% | −32.04% | −53.59% |
| 0H8T.L | Aclaris Therapeutics, Inc. | $6.14 | −6.69% | +105.92% | +237.38% |
| ABNX.PA | ABIONYX Pharma SA | 1.97 EUR | +5.79% | −49.58% | −31.34% |
| 0RAG.L | ABIONYX Pharma SA | 2.01 EUR | +3.40% | −48.40% | −29.10% |
| STX.L | Shield Therapeutics plc | 4.85 GBP | −15.65% | −50.76% | −37.42% |
| ALTHX.PA | THX Pharma Société Anonyme | 4.18 EUR | +5.16% | +83.92% | +73.96% |
| 0IIM.L | Esperion Therapeutics, Inc. | $3.19 | +0.14% | −14.28% | +44.65% |
| IMM.L | ImmuPharma plc | 3.41 GBP | −24.22% | −45.00% | +89.66% |
| ALDVI.PA | Advicenne S.A. | 1.75 EUR | +4.79% | −6.02% | +39.11% |
| 0RQJ.L | Saniona AB (publ) | 11.80 SEK | +0.47% | −44.08% | −12.20% |
| ALBPS.PA | Biophytis S.A. | 0.08 EUR | +422.88% | +28.41% | −50.31% |
| ANNX.ST | Annexin Pharmaceuticals AB (publ) | 13.60 SEK | +7.09% | −31.66% | −46.03% |
| PHR.WA | Pharmena S.A. | 3.14 PLN | +1.62% | +18.49% | −8.72% |
| BIOSGN.ST | Biosergen AB (publ) | 2.48 SEK | +262.31% | −93.80% | −94.62% |
| APTA.ST | Aptahem AB (publ) | 0.56 SEK | −15.96% | −51.69% | −67.65% |
| 0R55.L | BioSenic S.A. | 0.00 EUR | 0.00% | −4.76% | −25.93% |
| ALNEV.PA | Neovacs S.A. | 0.55 EUR | −31.22% | +6150.00% | −11.29% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.